TrialDiabetes, obesity & metabolism2026

First-In-Human Study of Mirogabalin (BM2216) Sustained-Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants.

Peiyang Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.